Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.62 |
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | CTSC | P53634 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.44 |
| ▸ | ALPL | P05186 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311735 | 0.91 | CTSC (0.50) | IGF1RSYKCTSCALPLGSK3B | |
| SCHEMBL6314422 | 0.87 | IGF1R (0.60) | IGF1RSYKEGFRALPLCDK2 | |
| SCHEMBL6312806 | 0.83 | IGF1R (0.47) | IGF1REGFRCDK2 | |
| SCHEMBL6312636 | 0.81 | CDK5 (0.47) | IGF1RSYKABL1 | |
| SCHEMBL6312590 | 0.80 | IGF1R (0.58) | IGF1REGFRALPLCDK2GSK3B | |
| SCHEMBL6318900 | 0.79 | IGF1R (0.58) | IGF1RSYKEGFR | |
| SCHEMBL6312020 | 0.79 | SYK (0.47) | IGF1RSYKEGFR | |
| SCHEMBL6642105 | 0.77 | DHFR (0.56) | IGF1REGFRCDK2 | |
| SCHEMBL6312056 | 0.77 | IGF1R (0.60) | IGF1REGFRCDK2 | |
| SCHEMBL6312155 | 0.77 | RAB9A (0.46) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | IGF1R 4054/4885SYK 928/4885CTSC 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.